Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) will be discussing 2Q20 financial results with the investment community.on 10th August 2020 at 8:30 AM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.xerispharma.com
Earnings Expectation
Xeris Pharmaceuticals, Inc. is reporting second quarter earnings results on Monday 10th August 2020, before market open. The consensus estimates from Thomson Reuters are loss of $ 0.73 per share. For the full year, analysts predict revenues of $ 13.49 million, while looking forward to loss of $ 2.99 per share.
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The companys lead product candidate is Gvoke HypoPen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes.
